Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on Pharma

AMD hit with lawsuit over hybrid bonding tech behind potent 3D V-Cache — Adeia claims company's gaming chip infringes 10 of its patents

Adeia has filed a pair of patent infringement lawsuits against AMD in the U.S. District Court for the Western District of Texas, accusing the chipmaker of using its hybrid bonding and advanced node technologies without permission.

Tom’s Hardware

Time for Reeves to recognise reality: AstraZeneca has killed stamp duty on shares

Shareholder-backed plans to upgrade US listing have exposed multiple flaws in tax that should be abolished or at least cut

The Guardian - UK

Palantir Q3 Preview: 'AI Juggernaut' Can Double Market Cap To $1 Trillion, Analyst Says

Palantir Technologies Inc (NASDQ:PLTR) reports third-quarter financial results on Monday after market close, with shares trading at all-time highs.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Biotech ETFs Come Alive As Illumina Soars 23% — Is The Genomics Winter Finally Over?

Biotech investors finally got a dose of good news this week. Illumina Inc (NASDAQ:ILMN) staged a powerful comeback, with the stock surging over 23% on Friday after topping its third-quarter guidance while narrowing its full-year revenue decline forecast. Now, the rally of this genomics firm has rippled through the ETF…

Benzinga

FDA Drug Chief George Tidmarsh Resigns After Allegations Of Power Misuse

George Tidmarsh, head of the Food and Drug Administration’s (FDA) drug center, resigned Sunday following allegations that he misused his regulatory power to financially harm a former business associate.

Benzinga

Pfizer Sues Rivals Metsera, Novo Nordisk Over Alleged Interference in Merger Talks

Pfizer sues Metsera and Novo Nordisk to block a rival bid in a high-stakes obesity drug merger.

International Business Times

Eli Lilly Seen In 'Pole Position' For Growth, Analysts Say

Eli Lilly and Co. (NYSE:LLY) reported better-than-expected third-quarter earnings on Thursday and boosted its annual forecast, sending the stock higher.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026

Gilead Sciences Inc (NASDAQ:GILD) on Thursday reported adjusted earnings of $2.47 per share, beating the consensus of $2.13.

Benzinga

DNA Sequencing Firm Illumina Sees Strong Clinical Market Momentum, Stock Soars

Illumina Inc. (NASDAQ:ILMN) stock is trading higher after the company reported better-than-expected third-quarter earnings.

Benzinga

AbbVie Raises 2025 Outlook Helped By Strong Immunology Growth, Boost Dividend

AbbVie Inc. (NYSE:ABBV) reported third-quarter 2025 sales of $15.78 billion on Friday, beating the consensus of $15.59 billion.

Benzinga

Baxter Trims Annual Outlook Again, Stock Hits 52-Week

Baxter International Inc. (NYSE:BAX) stock hit a 52-week low on Thursday, after the company again lowered its 2025 guidance.

Benzinga

Mounjaro And Zepbound Power Eli Lilly's 54% Revenue Jump In Q3, Hikes 2025 Forecast

Eli Lilly and Co. (NYSE:LLY) on Thursday reported better-than-expected third-quarter earnings and boosted its annual forecast, sending the stock higher.

Benzinga

New Walmart Partnership to Let Patients Buy Eli Lilly's Zepbound Without Insurance Hassles

Eli Lilly partners with Walmart to sell its weight-loss drug Zepbound nationwide, giving patients easier, insurance-free access through LillyDirect.

International Business Times

‘Patients will suffer’: tales from the frontline of the UK pharma crisis

The pricing standoff between government and industry has stalled research and put thousands of jobs at risk

The Guardian - UK

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Federal health officials push effort to spur cheaper biotech drugs

Federal regulators are trying to make it easier to develop cheaper alternatives to powerful drugs that many Americans depend on to treat autoimmune diseases or cancers

The Guardian - UK

UK must reform drug pricing to become life sciences superpower, says GSK boss

Shares jump on higher profits as Emma Walmsley is ‘hopeful’ standoff with NHS can be resolved

Benzinga

GSK Upgrades 2025 Financial Outlook, CEO Says Positioned Well For 2026

British pharmaceutical giant GSK Plc (NYSE:GSK) on Wednesday reported upbeat third-quarter results and upgraded its full-year 2025 guidance.

Benzinga

Incyte Delivers Robust Growth, But 2028 Patent Expiry Still Looms

Incyte Corporation's (NASDAQ:INCY) third-quarter revenue was $1.37 billion. The company beat the consensus of $1.26 billion.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Novartis Maintains Outlook Even As Generics Bite Into Profits

Swiss pharmaceutical major Novartis AG (NYSE:NVS) reported third-quarter 2025 results on Tuesday, reaffirming its full-year guidance as strong sales from key growth drugs offset mounting generic competition in the U.S.

The Guardian - AU

CSL share price plummets amid shareholder revolt over executive pay plans

US vaccination forecast leads to fall in stock price, while board survives spill in ‘second strike’ over pay concerns at AGM

Benzinga

Avidity Biosciences Soars After $72 Per Share Novartis Takeover

Avidity Biosciences, Inc. (NASDAQ:RNA) stock surged after announcing a $12 billion all-cash acquisition by Novartis AG (NYSE:NVS), marking one of the largest biotech buyouts of the year.

Benzinga

Janus Henderson, Avidity Biosciences, BridgeBio Pharma And Other Big Stocks Moving Higher On Monday

U.S. stocks were higher, with the Nasdaq Composite gaining around 1% on Monday.

Benzinga

EXCLUSIVE: Co-Diagnostics Inks JV With Saudi Arabia Firm For Middle East Market

Co-Diagnostics, Inc. (NASDAQ:CODX) announced on Monday that it has entered into a joint venture agreement with the Kingdom of Saudi Arabia (KSA) based Arabian Eagle Manufacturing.

Benzinga

Avidity Shareholders Win Big As Novartis Moves Fast On $12 Billion Deal

Avidity Biosciences, Inc. (NASDAQ:RNA) shares are rocketing premarket on Monday. On Sunday, the company agreed to merge with Novartis AG (NYSE:NVS) in a deal valued at $12 billion on a fully diluted basis.

Benzinga

Why Avidity Biosciences Shares Are Trading Higher By Around 42%; Here Are 20 Stocks Moving Premarket

Shares of Avidity Biosciences Inc (NASDAQ:RNA) rose sharply in pre-market trading after the company agreed to be acquired by Novartis AG (NYSE:NVS).

1 … 5 6 7 8

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

the Kingdom of Saudi Arabia

20 stories

the Western District

12 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.